Prothena Corp Public (PRTA) Revenue (2012 - 2026)
Prothena Corp Public (PRTA) posted quarterly Revenue of $51.1 million for Q1 2026, up 1706.36% year-over-year from $2.8 million in Q1 2025, and up 243157.14% quarter-over-quarter from $21000.0 in Q4 2025.
Prothena Corp Public (PRTA) Revenue (2012 - 2026) Analysis & Trends
Prothena Corp Public's Revenue history runs 15 years deep, the most recent figure standing at $51.1 million for Q1 2026.
- In Q1 2026, Revenue rose 1706.36% year-over-year to $51.1 million; the TTM figure through Mar 2026 stood at $57.9 million (down 57.99% YoY), while the FY2025 annual figure was $9.7 million, down 92.83% from the prior year.
- Revenue for Q1 2026 stood at $51.1 million, up from $21000.0 in the prior quarter.
- The five-year high for Revenue was $132.0 million in Q2 2024, with the low at $21000.0 in Q4 2025.
- The 5-year median for Revenue is $2.2 million (2023), against an average of $20.1 million.
- The sharpest annual moves came in 2023 and 2025: Revenue slumped 99.37% in 2023, then jumped 5556.0% in 2025.
- Prothena Corp Public's Revenue stood at $49.9 million in 2022, then plunged by 99.37% to $316000.0 in 2023, then surged by 571.84% to $2.1 million in 2024, then slumped by 99.01% to $21000.0 in 2025, then soared by 243157.14% to $51.1 million in 2026.
- Business Quant data shows PRTA's Revenue at $51.1 million in Q1 2026, $21000.0 in Q4 2025, and $2.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Prothena Corp Public | 458.45 Mn | 170.25 Mn | - | 1.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.01 Mn |
| Mar 31, 2026 | 51.08 Mn |
| Dec 31, 2025 | 21,000.00 |
| Sep 30, 2025 | 2.42 Mn |
| Jun 30, 2025 | 4.42 Mn |
| Mar 31, 2025 | 2.83 Mn |
| Dec 31, 2024 | 2.12 Mn |
| Sep 30, 2024 | 970,000.00 |
| Jun 30, 2024 | 132.01 Mn |
| Mar 31, 2024 | 50,000.00 |
| Dec 31, 2023 | 316,000.00 |
| Sep 30, 2023 | 84.87 Mn |
| Jun 30, 2023 | 4.02 Mn |
| Mar 31, 2023 | 2.17 Mn |
| Dec 31, 2022 | 49.92 Mn |
| Sep 30, 2022 | 1.52 Mn |
| Jun 30, 2022 | 1.31 Mn |
| Mar 31, 2022 | 1.15 Mn |
| Dec 31, 2021 | 1.17 Mn |
| Sep 30, 2021 | 139.17 Mn |